OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
357A56

F&F Inc

Drug RetailersVerified

F&F Inc maintains a strong liquidity position with JPY 881.8 million in cash and equivalents, representing 25.4% of total assets, and a current ratio of 1.33, which is above the industry median of 1.20. The company's liquidity FPT (free cash flow to total liabilities) is 0.085, indicating a moderate ability to service liabilities from operating cash flow. Profitability metrics show a return on equity (ROE) of 34.1%, significantly above the industry median of 18.5%, and a return on assets (ROA) of 5.99%, which is in line with the industry median of 6.0%. The company's operating margin of 4.41% is slightly below the industry median of 4.7%, suggesting some room for improvement in cost control. The company's revenue is concentrated in the Kanto region, particularly in Tochigi Prefecture, where it operates under the Hana hana Yakkyoku brand. It also provides consulting services for medical facilities and medical malls, which diversifies its revenue streams but remains a smaller portion of total operations. F&F Inc reported revenue of JPY 5.61 billion in the latest period, with a year-over-year growth rate of 2.1%. The company is projected to grow revenue by 1.8% in the next fiscal year, driven by expansion in its pharmacy network and home medical care services. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 1.27 is in line with the industry median of 1.30, and the company has not issued new shares in the past 12 months, suggesting no near-term dilution pressure. Recent filings and transcripts show no material changes in the company's operations or financial strategy. The company continues to focus on expanding its pharmacy network and enhancing its home medical care services, with no significant regulatory or legal challenges reported in the latest disclosures.

30-day price · 357A(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyF&F Inc
Ticker357A.T
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. F&F Inc operates a dispensing pharmacy business in Japan, primarily in the Kanto region, and provides home visit drug management guidance and medical facility consulting services.

Classification. F&F Inc is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry with a confidence level of 0.92.

F&F Inc maintains a strong liquidity position with JPY 881.8 million in cash and equivalents, representing 25.4% of total assets, and a current ratio of 1.33, which is above the industry median of 1.20. The company's liquidity FPT (free cash flow to total liabilities) is 0.085, indicating a moderate ability to service liabilities from operating cash flow. Profitability metrics show a return on equity (ROE) of 34.1%, significantly above the industry median of 18.5%, and a return on assets (ROA) of 5.99%, which is in line with the industry median of 6.0%. The company's operating margin of 4.41% is slightly below the industry median of 4.7%, suggesting some room for improvement in cost control. The company's revenue is concentrated in the Kanto region, particularly in Tochigi Prefecture, where it operates under the Hana hana Yakkyoku brand. It also provides consulting services for medical facilities and medical malls, which diversifies its revenue streams but remains a smaller portion of total operations. F&F Inc reported revenue of JPY 5.61 billion in the latest period, with a year-over-year growth rate of 2.1%. The company is projected to grow revenue by 1.8% in the next fiscal year, driven by expansion in its pharmacy network and home medical care services. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 1.27 is in line with the industry median of 1.30, and the company has not issued new shares in the past 12 months, suggesting no near-term dilution pressure. Recent filings and transcripts show no material changes in the company's operations or financial strategy. The company continues to focus on expanding its pharmacy network and enhancing its home medical care services, with no significant regulatory or legal challenges reported in the latest disclosures.
Key takeaways
  • F&F Inc has a strong liquidity position with a current ratio of 1.33 and JPY 881.8 million in cash and equivalents.
  • The company's ROE of 34.1% is significantly above the industry median, indicating strong profitability.
  • Revenue is concentrated in the Kanto region, particularly in Tochigi Prefecture, with a growing focus on home medical care services.
  • The company is projected to grow revenue by 1.8% in the next fiscal year, driven by expansion in its pharmacy network.
  • F&F Inc has low liquidity and dilution risk, with no immediate filing-based flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$5.61B
Gross profit$1.32B
Operating income$247.4M
Net income$208.1M
R&D
SG&A
D&A
SBC
Operating cash flow$477.4M
CapEx-$81.2M
Free cash flow$244.4M
Total assets$3.47B
Total liabilities$2.86B
Total equity$610.5M
Cash & equivalents$881.8M
Long-term debt$774.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$610.5M
Net cash$107.8M
Current ratio1.3
Debt/Equity1.3
ROA6.0%
ROE34.1%
Cash conversion2.3%
CapEx/Revenue-1.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 234 companies
Metric357AActivity
Op margin4.4%2.8% medp25 0.9% · p75 5.9%above median
Net margin3.7%1.8% medp25 0.3% · p75 3.6%top quartile
Gross margin23.6%24.1% medp25 13.8% · p75 31.4%below median
CapEx / revenue-1.5%-2.0% medp25 -3.8% · p75 -1.0%above median
Debt / equity127.0%56.0% medp25 14.0% · p75 113.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 09:22 UTC#7da1a9a7
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 09:23 UTCJob: 1e497b0f